- Current report filing (8-K)
09 Octubre 2012 - 12:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 17, 2012
Protect Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
|
|
|
Nevada
|
000-54001
|
27-1877179
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
|
2681 East Parleys Way, Suite 204, Salt Lake City, Utah
|
84109
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
|
Registrant
’
s telephone number, including area code:
|
(801) 322-3401
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
|
|
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.
|
|
On
May 17, 2012 the Company filed its annual report on Form 10-K
for the period ended
December 31, 2011
with the United States Securities and Exchange Commission. This filing was consummated before the Company
’
s auditors had formally
completed their audit or
authorized the filing to be made. Therefore, the Company
’
s management has determined that the previously issued financial stat
ements included in our annual report on Form 10-K
for the period ended
December 31
, 2011 should no longer be relied upon.
The Comp
any intends to file its audited
financial statements for the period ended
December 31
, 2011, with proper authorization from our independent auditors as soon as practicable.
The Company has informed Sadler, Gibb & Associates, LLC, the Company's independent registered public accounting firm of the matters disclosed in this filing, and has included as an exhibit to this 8-K filing the acknowledgement of Sadler, Gibb & Associates.
|
|
Item 4.02
|
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
|
|
|
16.1
|
Sadler, Gibb & Associates Letter
|
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly cause
d
this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated
October 9
, 2012
Protect Pharmaceutical Corporation
|
By: /s/ Geoff Williams
|
Geoff Williams, President
|
EXHIBIT INDEX
|
|
16.1
|
Sadler, Gibb & Associates Letter
|
Protect Pharmaceutical (PK) (USOTC:PRTT)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Protect Pharmaceutical (PK) (USOTC:PRTT)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024
Real-Time news about Protect Pharmaceutical Corporation (PK) (OTCMarkets): 0 recent articles
Más de Protect Pharmaceutical Corp (PL) Artículos de Noticias